Over-expression of MDR1 in amrubicinol-resistant lung cancer cells

This publication has 26 references indexed in Scilit:

• A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer
  Lung Cancer, 2010
• Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2010
• Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402
  Journal of Clinical Oncology, 2008
• Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells
  Biochemical Pharmacology, 2008
• Amrubicin for non-small-cell lung cancer and small-cell lung cancer
  Investigational New Drugs, 2007
• Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study
  Investigational New Drugs, 2006
• Uptake and Intracellular Distribution of Amrubicin, a Novel 9‐Amino‐anthracycline, and Its Active Metabolite Amrubicinol in P388 Murine Leukemia Cells
  Japanese Journal of Cancer Research, 1999
• Cytotoxicity of Amrubicin, a Novel 9‐Aminoanthracycline, and Its Active Metabolite Amrubicinol on Human Tumor Cells
  Japanese Journal of Cancer Research, 1998
• Comparative activity of doxorubicin and its major metabolite, doxorubicinol, on fibroblasts: A morphofunctional study
  Experimental and Molecular Pathology, 1991
• Antitumor Activities of a Novel 9‐Aminoanthracycline (SM‐5887) against Mouse Experimental Tumors and Human Tumor Xenografts
  Japanese Journal of Cancer Research, 1989